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Background: Patients with severe mental illness are at increased risk of developing metabolic disorders. The risk of
metabolic syndrome in the Hong Kong general population is lower than that observed in western countries;
however the prevalence of metabolic syndrome in patients with severe mental illness in Hong Kong is unknown.
Method: This cross-sectional study aimed to estimate the prevalence of metabolic syndrome in patients with
severe mental illness in Hong Kong and to identify the relationships between metabolic syndrome and socio-
demographic, clinical and lifestyle factors.
Results: A total of 139 patients with a diagnosis of severe mental illness participated in the study. The unadjusted
prevalence of metabolic syndrome was 35%. The relative risk of metabolic syndrome in comparison with the
general Hong Kong population was 2.008 (95% CI 1.59-2.53, p < 0.001). In a logistic regression model sleep
disruption and being prescribed first generation antipsychotics were significantly associated with the syndrome,
whilst eating less than 3 portions of fruit/vegetables per day and being married were weakly associated.
Conclusion: The results demonstrate that metabolic syndrome is highly prevalent and that physical health
inequalities in patients with severe mental illness in Hong Kong are similar to those observed in western countries.
The results provide sufficient evidence to support the need for intervention studies in this setting and reinforce the
requirement to conduct regular physical health checks for all patients with severe mental illness.
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The physical health of patients with severe mental illness
(SMI) in western societies has been shown to be ex-
tremely poor. It is estimated that patients with SMI have
a life expectancy up to 25 years less than the general
population [1] and that lifespan is worsening over time.
Hong Kong has one of the highest life expectancies in
the world [2]. To date there have been few empirical
studies that provide estimates of whether physical health
inequalities for patients in Hong Kong with SMI are
similar to those observed in western countries.* Correspondence: daniel.bressington@canterbury.ac.uk
1The Department of Health, Well-being and the Family, Canterbury Christ
Church University, North Holmes Road, Canterbury, Kent CT1 1QU, UK
Full list of author information is available at the end of the article
© 2013 Bressington et al.; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumStudies in the UK and USA demonstrate that patients
with SMI are more likely to develop cardiovascular disease
and have a much higher rate of metabolic disorders than
the general population [3]. A UK study [4] involving
almost 800 SMI patients screened for physical health is-
sues identified that 66% of patients had a Body Mass Index
of over 25 and that risk factors for cardiovascular disease
were very common. Metabolic syndrome (MES) is also
commonly seen in patients with SMI; a study involving
689 participants in the USA [5] identified that males with
schizophrenia were 138% more likely and females 251%
more likely to have MES than the general population.
MES is defined by the International Diabetes Federation
as a collection of clinical indicators; including central
obesity (measurable by waist circumference), hypertensionntral Ltd. This is an Open Access article distributed under the terms of the
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MES is reported to be a key risk factor for cardiovascular
disease and diabetes mellitus both of which impact heavily
upon life quality and expectancy [6].
To our knowledge the prevalence of metabolic
syndrome in patients with SMI in Hong Kong has not
been reported in the literature to date. However previ-
ous research has explored the prevalence in the general
population, for example a study involving over 7,000
people estimated that the unadjusted prevalence of
MES using the International Diabetes Federation (IDF)
criteria was 17.6% [6]. An earlier smaller study [7]
using the same IDF criteria estimated a prevalence rate
of 7.4% in a Hong Kong working population. Findings
reported by Thomas et al [8] reinforce the importance
of identifying and treating MES in a Hong Kong setting
as the syndrome was associated with an increased
risk of cardiovascular disease (hazard ratio 6.39, 95%
CI 1.40-29.2) and increased all-cause mortality risk
(hazard ratio 2.02, 95% CI 1.02-4.00).
Study aims
The aims of this study are to:
 Estimate the prevalence of metabolic syndrome in
community dwelling patients with SMI in Hong
Kong;
 Identify the relationships between metabolic
syndrome and socio-demographic, clinical,
treatment and lifestyle factors in the study
population.
Methods
Study design
This exploratory study uses a cross-sectional survey
design to estimate the prevalence of MES in the sample
population. We report an analysis of baseline data from
the initial findings of a larger on-going prospective case
series study. In order to ensure that the sample size
obtained provided adequate statistical power we performed
a power calculation. Based on the assumption that there
are 800 patients with SMI registered with the CPN service,
with a margin for error of ±10% and a 95% confidence
interval, we calculated that we would require a sample size
of 86 participants.
Recruitment and selection of participants
30 Community Psychiatric Nurses (CPNs) working in
the clinical setting screened and recruited participants.
The study used a convenience sampling approach on a
sequential basis, where each CPN asked the first five
service users that they were routinely scheduled to
visit and who met the inclusion criteria to participate
in the study.Inclusion criteria
 Male or female. Aged over 18; with a diagnosis of
Severe Mental Illness (SMI) defined by a case-note
diagnosis of any psychotic disorder (i.e.
schizophrenia, schizoaffective disorder), bipolar
affective disorder (type 1 or 2) or psychotic
depression.
Exclusion criteria
 Any service user who did not have capacity to
provide informed consent.
Ethical considerations
Ethical approval was obtained from the Hong Kong New
Territories West Cluster Clinical and Research Ethics
Committee. Participants were required to provide written
informed consent in order to participate, the participant
information sheets clearly stated that declining to take
part would not negatively influence their clinical
treatment. We chose to ask CPNs to recruit partici-
pants and collect data for a number of reasons. As
recruitment and data collection was mainly carried
out in the home environment we felt that it would be
more appropriate for a CPN who knew the service
users and their families well to carry out the examinations
rather than an independent researcher. We also wanted to
ensure that the CPNs would be immediately aware of any
physical health concerns identified by the screening and
hence recommend or provide clinical interventions as
deemed appropriate.
Data collection
The Health Improvement Profile (HIP) [9] was used as a
screening tool to collate data about the physical health
state of individuals and their health-related behaviours.
The community psychiatric nurses (CPNs) who collected
data were trained how to use the HIP and carry out
the required physical examinations shortly before the
study commenced.
The HIP is a 27 item tool that is gender specific and is
designed to be used as both a screening measure and a
tool to facilitate interventions aimed to improve physical
health and associated health behaviours [9]. Parameters
are provided for each item in order that aspects of
health and lifestyle can be flagged as red (indicating that
an intervention is required) or green (no intervention
recommended). The authors conducted literature reviews
to establish the “normal” and “at risk” ranges and developed
the tool through a series of pilot studies [10]. The utility
and acceptability of the HIP as a screening tool was
established in an exploratory case series [11]. In this study
we analysed the health behaviours that our literature
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metabolic syndrome.
The HIP was originally designed for use in a western
population and therefore we modified the parameters of
the HIP that relate to obesity to reflect the most recent
guidelines for the assessment of MES in an Asian
population. A BMI of 23 or over was used to represent
being overweight and a waist circumference of 90 cm for
males was used to determine central obesity. In line
with recommendations from the International Diabetes
Federation [12] we used the following criteria to determine
MES in study participants: (Table 1).
In addition to the HIP data we also recorded a range
of demographic and clinical characteristics: age, gender,
education, marital status, diagnosis, duration of illness,
employment status and prescribed medication. CPNs
carried out basic physical examinations and data from
blood tests were obtained from the servicer users’ most
recent outpatient medical records. All plasma glucose
levels were obtained whilst participants were fasting.Table 2 Demographic and clinical characteristics of
participants
Demographic Number (%)
Gender
Male 62 (45)
Female 77 (55)
Marital Status
Single 93 (67)
Married 36 (26)
Widowed 8 (6)
Unknown 2 (1)
Educational Level
None 6 (4)
Primary 49 (35)
Secondary 80 (58)Data analysis
Data were analysed using SPSS (version 17). We used
the presence of MES as the dependent variable and
conducted Chi-square tests or Fisher’s exact tests to
identify differences between demographic, clinical, treat-
ment related and health behaviour variables in those with
and without MES (in order that potential associations
with MES could be highlighted). We also conducted
independent samples T-tests for the continuous variables
to determine differences in mean values for patients with
and without MES. In a secondary analysis Chi-square
tests were used to determine differences in cardiovascular
risk factors according to gender.
In order to identify the independent risk factors
associated with metabolic syndrome, the variables that are
not part of the criteria for the syndrome were selectedTable 1 International diabetes federation criteria for
metabolic syndrome in an Asian/Chinese population
Central obesity - defined by with ethnicity specific waist circumference
of≥ 80 cm (females) and≥ 90 cm (males) plus any two of the following
four factors:
Raised triglycerides ≥ 150 mg/dL (1.7 mmol/L)
or specific treatment for this lipid abnormality
Reduced HDL
cholesterol
< 40 mg/dL (1.03 mmol/L) in males
< 50 mg/dL (1.29 mmol/L) in females
or specific treatment for this lipid abnormality
Raised blood
pressure
Systolic BP ≥ 130 or diastolic BP≥ 85 mm Hg or
treatment of previously diagnosed hypertension
Raised fasting
plasma glucose
(FPG)≥ 100 mg/dL (5.6 mmol/L),
or previously diagnosed type 2 diabetes
(adapted from IDF; 2006) [12].from a forward selection criterion by sequentially including
variables in the logistic regression model until none were
significant at the 0.2 level. We included variables in the
final regression model that were significantly associated
at the p < 0.05 level and also those weakly associated at
the p < 0.10 level. In order to calculate the relative risk of
developing MES in our sample we used data reported by
Ko and Tang [6] for the prevalence in the general Hong
Kong population.
Results
A total of 139 participants met the analysis criteria and
had sufficient data recorded to estimate the prevalence
of MES. Data were collected during February 2012.
Demographic and clinical characteristics of study
participants
Table 2 details the demographic and illness characteristics
of study participants.University/Post Graduate 4 (3)
Diagnosis
Schizophrenia and related disorders 97 (70)
Bipolar Affective Disorder (BPAD) 14 (10)
Psychotic depression 19 (14)
Other (i.e. schizoaffective disorder;
non-specified psychosis)
8 (6)
Unknown 1 (<1)
Employment Status
Unemployed 68 (49)
Employed 33 (24)
Homemaker 32 (23)
Retired/other 4 (3)
Unknown 2 (1)
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range 18-70). All patients were Hong Kong Chinese, the
majority were female and two-thirds were single.
Around half of participants were unemployed. In terms
of educational level; a third had completed primary
school, over half had completed secondary education
and very few (3%) had further/higher qualifications.
In terms of illness/treatment characteristics; almost
three quarters of patients had a diagnosis of schizophrenia
and related disorders, 19 (14%) had psychotic depression
and one in ten were diagnosed with bipolar affective
disorder. On average they had been in contact with
psychiatric services for 14 (sd = 10.8) years.
Medications prescribed, individual prevalence of MES
in each medication and their statistical association with
MES are detailed in Table 3.
Over half of participants were prescribed second
generation (atypical) antipsychotic medication, and just
over a third was prescribed first generation (typical) anti-
psychotics. Around one in ten patients was being treated
with clozapine. Around a quarter of service users were
prescribed an antihypertensive, only 16 (12%) were being
offered diabetes treatments and very few (n = 6, 4%) were
prescribed a statin.Table 3 Prescribed medication and association with MES
Prescribed first
generation
antipsychotics
Number
(%)
Number of patients
with MES (%)
χ2, P-value
Yes 51 (37) 25 (49) χ2 = 6.69, p = 0.01
No 88 (63) 24 (27)
Prescribed Second Generation Antipsychotics
Yes 81 (58) 26 (32) NS
No 58 (42) 23 (39)
Prescribed Clozapine
Yes 16 (12) 5 (31) NS
No 123 (89) 44 (36)
Prescribed Long Acting Antipsychotic Injection
Yes 33 (24) 14 (42) NS
No 106 (76) 35 (33)
Prescribed an antihypertensive
Yes 32 (23) 18 (56) χ2 = 8.03, p < 0.01
No 107 (77) 31 (29)
Prescribed a statin
Yes 6 (4) 6 (100) χ2 = 11.52, p < 0.01
No 133 (96) 43 (32)
Prescribed diabetes treatment
Yes 16 (12) 12 (75) χ2 = 12.52, p < 0.01
No 123 (89) 37 (30)
P for association between prescribed medications and metabolic syndrome,
tested by χ2 test.
NS = Not significant.Prevalence of MES and other cardiovascular risk factors
The prevalence, relative risk of MES and cardiovascular
risk indicators split according to gender are shown in
Table 4.
The unadjusted prevalence of MES in the entire
sample was just over a third (35%, n = 49). When data
are split according to gender; 31% (n = 19) of males and
39% (30) females met the diagnostic criteria for MES.
The vast majority of patients (80%, n = 111) had a BMI
of 23 or over.
Around a quarter of participants (24%, n = 33) were
reported to be hypertensive, raised triglycerides were
observed in 34 (25%) of service users and 32 (23%) were
found to have reduced levels of HDL cholesterol. Raised
fasting plasma glucose levels were detected in 17 (12%)
of patients.
In comparison with males a higher percentage of
women were observed to be overweight, however
Chi-square tests demonstrate that the only cardio-
vascular risk factor that is significantly more likely
in women is a waist circumference over recommended
limits (χ2 = 11.40,p = 0.001).
Health behaviours of study participants
The self-reported health behaviours of participants and
associations with MES are shown in Table 5. Very few
participants used cannabis (n = 3, 2%) or drank more
than 4 units of alcohol per day (n = 7, 5%), similarly few
participants consumed more than 600 mg of caffeine
each day (n = 8, 6%) and 38 (27%) smoked tobacco. The
majority of patients (n = 86, 62%) exercised for less than
recommended levels (30 minutes per day five times per
week) and around a fifth ate more than 3 portions of fat
per day (n = 27, 19%) and 26 (19%) consumed less than
three portions of fruit/vegetables per day.
Associations with MES
Demographic and clinical characteristics
None of the demographic or clinical characteristics were
found to be significantly associated with MES in this
group of patients. However, independent sample T-tests
demonstrate that there is a trend towards the mean
duration of illness being longer in the group of patients
with metabolic syndrome (t = 1.94, df = 137, p = 0.054).
Treatment-related variables
There were significant relationships observed between
MES and medical treatments for associated issues;
diabetes treatments (χ2 = 12.52, p < .001), statins (χ2 = 11.52,
p < .001) and antihypertensives (χ2 = 8.03, p < .01) were all
strongly associated with MES. As these variables constitute
elements of the criteria for MES this result was expected
and therefore the associations are not particularly
clinically relevant.
Table 4 Prevalence of MES (with relative risk) and indicators of cardiovascular risk (split according to gender)
Male n = 62, (%) Female n = 77, (%) Total n, (%) χ2, P-value*
Metabolic Syndrome present 19 (31) 30 (39) 49 (35) NS
Relative Risk of Metabolic Syndrome
(95% CI, P value)**
1.737 (1.18-2.54,
p < 0.01)
2.230 (1.67-2.97,
p < 0.01)
2.008 (1.59-2.53,
p < 0.01)
BMI overweight- Hong Kong criterion (≥23) 48 (77) 63 (82) 111 (80) NS
BMI overweight- International criterion (≥25) 34 (55) 45 (58) 79 (57) NS
Waist Circumference (males ≥90 cm,
females≥ 80 cm)
20 (32) 47 (61) 67 (48) χ2 = 11.40,
p < 0.01
Hypertension – Blood pressure≥ 140/90 12 (19) 21 (27) 33 (24) NS
Hypercholesterolemia – Total Cholesterol ≥6.2 mmol/L 15 (24) 16 (21) 31 (22) NS
Raised LDL cholesterol – LDL ≥ 4.1 mmol/L 11 (18) 12 (16) 23 (16) NS
Reduced HDL cholesterol – HDL <1.00 mmol/L
(males), <1.30 mmol/L (females)
13 (21) 19 (25) 32 (23) NS
Raised fasting plasma glucose -≥ 7.00 mmol/L 8 (13) 9 (12) 17 (12) NS
Raised triglycerides - ≥2.2 mmol/L 17 (27) 17 (22) 34 (25) NS
*P for significant differences in cardiovascular risk according to gender, tested by χ2 test.
NS = not statistically significant.
** Data reported by Ko and Tang [6] for the prevalence of MES in the general Hong Kong population was used to calculate the relative risk in this sample.
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only 1st generation antipsychotics were significantly
associated with MES (χ2 = 6.69, p < .01). Surprisingly there
was no relationship observed between numbers of anti-
psychotics prescribed, clozapine or atypical antipsychotics
and MES.
Health behaviour related variables
Of all the health-behaviour related variables only sleep
disruption (<3 hours or >8 hours per night) was associated
with MES (χ2 = 4.64, p = 0.031). A secondary analysis
further demonstrated that when all the health behaviour
variables are grouped together as one risk factor they were
not significantly associated with MES.Table 5 Health behaviours of participants
Health behaviour Total n,
(%)
χ2, P-value
Smoking status (smoker/passive smoker) 38, (27) NS
Alcohol intake (>4 units daily) 7, (5) NS
Exercise (< 30 minutes a day for
5 days per week)
86, (62) NS
Diet fruit and vegetables
(≤2 daily portions)
26, (19) NS
Diet Fats (≥ 3 portions per day) 27, (19) NS
Fluid Intake (<1 L or >3 L per day) 9, (7) NS
Caffeine Intake (≥600 mg/day) 8, (6) NS
Disrupted sleep (>8 h or <3 h) 38, (27) χ2 = 4.64,p < 0.05
Cannabis use (occasional or regular) 3, (2) NS
P for association between health behaviour and metabolic syndrome, tested
by χ2 test.
NS = Not statistically significant.Independent related variables
Table 6 shows the adjusted odds ratios for independent
risk factor variables which were significant at the 0.2
level in the regression model. In the logistic regression
model sleep disruption (OR 3.57 (95% CI 1.45, 8.79),
p = 0.006), being prescribed first generation antipsychotics
(OR 3.83 (95% CI 1.63, 9.04), p = 0.002) were significant
risk factors for MES. The model also shows that
eating less than 3 portions of fruit/vegetables per day
(OR 2.19 (95% CI 0.86,5.59), p = 0.099) and being married
(OR 0.45 (95% CI 0.19,1.09), p = 0.077) were weakly
significant risk factors.
Discussion
Metabolic syndrome is highly prevalent in this cohort of
patients; 35% of the participants (31% of men and 39%
of women) met the IDF criterion. Previous studies show
that the prevalence of MES in patients with SMI differs
in accordance with the population being studied. Research
carried out in the USA has estimated the prevalence of
MES in SMI to be between 28.7% [13] and 60% [14]. A
similarly high prevalence rate of 54% was reported in an
Australian study [15]. Whilst a Canadian study calculatedTable 6 Adjusted odds ratios for the presence of
metabolic syndrome
Factor Odds ratio (95% CI) p-value
First generation antipsychotics 3.83 (1.63,9.04) 0.002
Disrupted sleep (>8 h or <3 h) 3.57 (1.45,8.79) 0.006
Marital status (single/widowed/
divorced vs. married)
0.45 (0.19,1.09) 0.077
Diet fruit and vegetables 2.19 (0.86,5.59) 0.099
Bressington et al. BMC Psychiatry 2013, 13:87 Page 6 of 8
http://www.biomedcentral.com/1471-244X/13/87a prevalence rate of 44.7% [16] and a Finnish project [17]
estimated 37.1%. Studies that explore Asian populations
tend to report lower rates of MES in SMI than western
countries, for example Littrell et al [18] report that 22% of
patients with schizophrenia in Taiwan had MES, whilst in
Thailand Srissurapanont et al [19] estimated a prevalence
rate of 20%. Although direct comparisons with other
countries are complicated by the differing prevalence rates
in the general populations, our results suggest that the
rates of MES in patients with SMI in Hong Kong are likely
to be lower than those observed in western populations
and higher than in some other Asian countries.
It is perhaps more clinically relevant to report the
increased risk of MES in SMI with the general population
(please see Table 4). In the general Hong Kong community
the unadjusted prevalence rates of MES have been
reported as 17.6% (17.7% of males and 17.5% of females)
[6]. As our results indicate that 35% of patients with SMI
have MES (31% men and 39% women) the relative risk of
metabolic syndrome in comparison with the general Hong
Kong population is 2.008 (95% CI 1.59-2.53, p < 0.001). The
relative risk for males is 1.737 (95% CI 1.18-2.54, p = 0.005)
and for females is 2.230 (95% CI 1.67-2.97, p < 0.001).
McEvoy et al., [5] estimate the increased risk of MES in
SMI to be 138% for men and 251% for women in the USA.
Therefore, although the overall rates of MES in patients
with SMI in Hong Kong are lower than in some western
countries the increased risk is potentially higher for men,
although slightly lower for women, compared to rates
reported in the USA.
Despite the high prevalence of MES observed in this
study few patients were prescribed medical treatments
for dyslipidaemia or diabetes. McEvoy et al., [5] reported
similar findings in the USA; significant percentages of
SMI patients with these conditions were not receiving
treatment. This finding suggests the requirement for
enhanced collaborative working between primary care and
specialist mental health services, in order that patients can
receive prompt appropriate medical treatments once such
conditions are identified.
None of the demographic or clinical characteristics
were found to be significantly associated with MES in
our initial bivariate analysis. However, the relationship
between duration of illness and MES was found to be
approaching statistical significance. The prevalence of
MES in women was higher than in men, but the difference
was not significant (χ2 = 1.04, p = 0.31). These findings are
consistent with results reported by John et al., [15] however
many other studies identify a clear link between age,
gender, duration of psychiatric illness and MES [19,20].
The multivariable logistic regression model highlights
that patients in this study who were married were
slightly more likely to have developed MES than those
who were single/divorced or widowed (OR 0.45 (95% CI0.19,1.09), p = 0.077). Previous studies that explore the
relationship between marital status and MES have
reported equivocal results, for example married women
in the general population of USA were found to have a
lower prevalence of MES than those who were single
[21] whilst no such relationships were observed in a
study of over 2000 patients in Taiwan [22]. One possible
explanation for our result is an inter-relationship between
MES, marriage and diet.
Previous authors [23] have proposed that that the
unhealthy lifestyles of patients with SMI contribute
towards the aetiology of MES. Unexpectedly in the
bivariate analysis we did not identify any significant
associations between lifestyle variables (other than sleep)
and MES in this sample. However, eating less than
recommended levels of fruits and vegetables was found
to be a weak predictor of MES in the final multivariate
regression model. The relationship between poor diet
and MES in people with SMI has been reported in many
studies i.e. [24]; these previous results and our observations
suggest that health promotion approaches aimed at
reducing cardiovascular risk need to consider incorporating
dietary interventions.
The association between sleep disruption and MES
was significant, and the regression model also identified
sleep disruption as being a risk factor for the syndrome.
This finding has previously been reported by a number
of authors, for example; Hall et al [25] conducted a
study of over 200 participants in the general population
in the USA and concluded that there is an increased risk
of developing MES of 45% in people who sleep more or
less than 7-8 hours per day. The association between
short sleep duration and MES may be explained by the
relationship identified between obstructive sleep apnoea
and many indicators of MES, for example; obesity,
hypertension, diabetes and dyslipidaemia [26]. The evi-
dence relating to an association between a long duration
of sleep and MES is less clear; however some authors
conclude that risk factors for MES are more common in
long sleepers, i.e. type 2 diabetes [25]. The relationship
between excess sleep and MES observed in our study
may also be explained by the likelihood that some of the
more sedating antipsychotic drugs have been observed
to be implicated in the development of MES [27], or
potentially that those participants with sleep disruption
may be more likely to be engaging in a generally more
sedentary lifestyle.
First generation (or typical) antipsychotics were observed
to have an association with MES and were also significant
in our regression model, a surprising finding given that
many studies demonstrate that second generation antipsy-
chotics are more likely to be associated with MES than first
generation drugs [27]. However, our findings are supported
by a number of studies that identify the same association
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that we did not perform analysis for the association of
individual atypical antipsychotic preparations with MES
(other than clozapine), and this may be a confounder as
some atypical antipsychotics have been reported to be
more likely to cause weight gain than others [27]. Nor
did we collect data relating to the extent of adherence
with antipsychotic medications. It is therefore not possible
to draw firm conclusions about the potential impact of
these medications on physical health.
In the literature there is continued debate about the
likelihood of atypical antipsychotics being involved in
the aetiology of MES [15]. The current physical health
policy in the clinical setting in which our research was
carried out recommends that patients receiving atypical
(or second generation) antipsychotics require at least
yearly screening for metabolic abnormalities; our results
suggest that this should be extended to anyone with a
diagnosis of a severe mental illness irrespective of the
type of antipsychotic prescribed. Although the mean
duration of illness in those with MES was not significantly
different to those without MES, the observed trend and
previous research suggests that a longer duration of illness
may increase the risk of MES. This may also provide a
potential explanation of why typical antipsychotics are
associated with MES in this study; current treatment
guidelines recommend the use of atypicals for patients
newly diagnosed and therefore it is likely that those who
are taking typical medications have been established on
these for some time and subsequently may have a longer
duration of illness.
There are a number of study limitations that could
have influenced our findings and which also make it
difficult to generalise the results to other countries or
the wider eastern world. This study has a cross-sectional
design, includes a relatively small number of patients
with SMI and uses a convenience sampling approach
rather than utilising an epidemiological sampling strategy.
The small numbers of participants may account for the
lack of statistical associations observed between MES and
the independent variables. Recruitment bias is possible
because participants were invited to take part by their
clinicians on a sequential basis. Blood test results were
obtained from recent data recorded in out-patient case
notes; it is possible that service users whom have attended
for tests may have been invited due to concerns about
their physical health and therefore be at a relatively higher
risk of MES than those patients with SMI who have not
had blood tests recorded recently.
Although this study has a relatively small number of
participants, the findings provide sufficient evidence to
support the need for intervention studies in this setting
and reinforce the requirement to conduct regular MES
screening. Future research in Hong Kong should alsoaim to establish the prevalence of MES in patients
with SMI using a larger sample size and a randomised
epidemiological sampling strategy.Conclusion
The results demonstrate that physical health inequalities
in patients with severe mental illness in Hong Kong are
similar to those observed in western countries. MES was
found to highly prevalent in this population as 35% of
the participants (31% men and 39% women) met the
IDF diagnostic criteria. The relative risk of metabolic
syndrome in this cohort in comparison to the general
Hong Kong population is 2.008 (1.737 for males and
2.230 for females). In this study being prescribed first
generation antipsychotics and sleep disruption are
significant risk factors for MES, whilst eating less than
recommended levels of fruits/vegetables and being
married are weakly associated with the syndrome. The
findings therefore suggest that clinicians in Hong Kong
should conduct regular physical health screening for
MES irrespective of the type of antipsychotic prescribed,
ensure that patients with identified physical comorbidities
receive medical treatment promptly and increase the
focus of clinical interventions towards physical health
promotion strategies.
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